Study guide

Blood pressure and cardiovascular risk

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Blood pressure and cardiovascular risk

Key Takeaways Explain This Topic AI

Five-year Australian CVD risk is low below 5%, intermediate from 5 to below 10%, and high from 10%.

Established CVD requires secondary prevention rather than primary-risk calculation.

Lifestyle and medicine decisions should consider absolute risk and patient preferences.

Last updated: October 2026

Systemic Hypertension & Peripheral Vascular Disease

Systemic hypertension is the single greatest modifiable risk factor for cardiovascular disease, stroke, chronic kidney disease, and vascular dementia in Australia. Modern clinical practice shifts the therapeutic focus from isolated blood pressure thresholds to comprehensive absolute cardiovascular disease (CVD) risk assessment , ensuring that lifestyle interventions and pharmacotherapy are targeted according to overall vascular risk.

Diagnostic Criteria and Blood Pressure Measurement Modalities

Accurate measurement of blood pressure is essential to avoid misclassification:

In-Clinic Measurement : The patient should be seated quietly in a chair with back supported for at least 5 minutes prior to measurement, feet flat on the floor, and the arm supported at heart level. An appropriately sized cuff must be used (bladder encircling 80 % to 100 % 80\%\text{ to }100\% 80% to 100% of the arm circumference). A diagnosis of hypertension requires a clinic systolic blood pressure (SBP) ≥ 140 mmHg \ge 140\text{ mmHg} ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg \ge 90\text{ mmHg} ≥ 90 mmHg confirmed across at least two separate clinical consultations, unless the baseline reading is severely elevated ( ≥ 180 / 110 mmHg \ge 180/110\text{ mmHg} ≥ 180/110 mmHg ) or accompanied by acute target organ damage.

Ambulatory Blood Pressure Monitoring (ABPM) : Recognized as the reference standard out-of-office modality. Confirms hypertension if the 24-hour mean is ≥ 130 / 80 mmHg \ge 130/80\text{ mmHg} ≥ 130/80 mmHg , the daytime (awake) mean is ≥ 135 / 85 mmHg \ge 135/85\text{ mmHg} ≥ 135/85 mmHg , or the nighttime (asleep) mean is ≥ 120 / 70 mmHg \ge 120/70\text{ mmHg} ≥ 120/70 mmHg . ABPM also identifies abnormal nocturnal non-dipping patterns (failure of SBP to fall by > 10 % > 10\% > 10% at night), which is a powerful independent predictor of adverse cardiovascular and cerebrovascular outcomes.

Home Blood Pressure Monitoring (HBPM) : Recommended for confirming the diagnosis and long-term surveillance. The patient performs duplicate morning and evening measurements for 7 consecutive days. Day 1 measurements are discarded, and the mean of the remaining readings is calculated. A home average ≥ 135 / 85 mmHg \ge 135/85\text{ mmHg} ≥ 135/85 mmHg confirms hypertension.

Phenotypic Discrepancies :

White-Coat Hypertension : Elevated in-clinic blood pressure with normal ABPM/HBPM readings. Carries modest long-term risk; managed with lifestyle modification and annual surveillance.

Masked Hypertension : Normal clinic blood pressure with elevated out-of-office ABPM/HBPM readings. Carries a cardiovascular risk equivalent to sustained hypertension and requires formal antihypertensive drug therapy.

Australian Absolute Cardiovascular Disease Risk Assessment (2023+ Guidelines)

In 2023, the Australian Cardiovascular Health and Prevention Alliance and the National Heart Foundation released the updated Australian Guideline for assessing and managing cardiovascular disease risk . This replaced the older Framingham-based risk charts with a modern Australian algorithm derived from the New Zealand PREDICT cohort, recalibrated for contemporary Australian population incidence:

Target Screening Populations

All asymptomatic individuals aged 45 to 79 years without pre-existing CVD.

All First Nations (Aboriginal and Torres Strait Islander) peoples aged 30 to 79 years , reflecting earlier onset of vascular disease and health inequities.

People with diabetes aged 35 to 79 years .

Stratification Categories (5-Year Risk of a Cardiovascular Event)

Low Absolute Risk ( < 5 % < 5\% < 5% ) : Managed with lifestyle interventions (dietary modification, physical activity, alcohol limitation, smoking cessation) with risk recalculation every 5 years.

Intermediate Absolute Risk ( 5 % to below 10 % 5\%\text{ to below }10\% 5% to below 10% ) : Lifestyle modification combined with consideration of blood pressure-lowering and lipid-lowering pharmacotherapy if risk factors persist or reclassifying risk modifiers are present (e.g., elevated coronary artery calcium score, persistent socioeconomic disadvantage, family history of premature CVD).

High Absolute Risk ( ≥ 10 % \ge 10\% ≥ 10% ) : After discussing benefits and harms, prescribe blood-pressure-lowering and lipid-modifying treatment unless contraindicated or clinically inappropriate, alongside lifestyle support. Consider baseline pressure, adverse-effect risk and the patient’s preferences.

Clinically determined high risk

Established cardiovascular disease requires secondary prevention. In primary prevention, confirmed familial hypercholesterolaemia or moderate-to-severe CKD establishes high risk without calculation: sustained eGFR below 45 mL/min/1.73 m2 or persistent ACR above 25 mg/mmol in men or 35 in women. Diabetes alone after 60, BP above 180/110 or total cholesterol above 7.5 are older automatic categories and should not replace the current Australian algorithm. Treat severe hypertension and investigate very high lipids independently on their clinical merits.

For eligible patients, low five-year risk is below 5%, intermediate is 5 to below 10%, and high is at least 10%. Discuss lifestyle, preventive medication, benefits and adverse effects using absolute risk and preferences. Reclassification factors and secondary causes can modify the plan.

First-Line Pharmacotherapy and Antihypertensive Selection

Contemporary Australian guidelines recommend three core drug classes for initial therapy:

Angiotensin-Converting Enzyme (ACE) Inhibitors or Angiotensin Receptor Blockers (ARBs) :

Examples: Perindopril, ramipril, candesartan, telmisartan.

First-line for patients with type 2 diabetes, chronic kidney disease with albuminuria, heart failure, or history of myocardial infarction.

Adverse Effects: Dry cough occurs in 5 % to 10 % 5\%\text{ to }10\% 5% to 10% of patients on ACE inhibitors due to bradykinin accumulation (necessitating a switch to an ARB); angioedema; hyperkalaemia.

Dihydropyridine Calcium Channel Blockers (CCBs) :

Examples: Amlodipine, lercanidipine.

Potent vasodilators especially efficacious in older individuals and isolated systolic hypertension.

Adverse Effects: Dose-dependent peripheral ankle oedema (caused by precapillary arteriolar vasodilation rather than generalized fluid retention; does not respond to loop diuretics; combination with an ACEi/ARB reduces capillary hydrostatic pressure and resolves the oedema).

Thiazide-Like Diuretics :

Examples: Indapamide ( 1.25 to 2.5 mg 1.25\text{ to }2.5\text{ mg} 1.25 to 2.5 mg daily) or chlorthalidone .

Clinical Note : Thiazide-like diuretics are clinically superior to hydrochlorothiazide (HCTZ) due to longer half-lives, greater 24-hour ambulatory blood pressure reduction, and robust evidence of cardiovascular event reduction in randomized clinical trials.

Adverse Effects: Hypokalaemia, hyponatraemia, hyperuricaemia (may precipitate acute gout), and mild dyslipidaemia.

Treatment Strategies

Monotherapy : Suitable for mild hypertension (Grade 1) with low absolute cardiovascular risk.

Dual Combination Therapy : Recommended as first-line therapy for patients with baseline blood pressure ≥ 20 / 10 mmHg \ge 20/10\text{ mmHg} ≥ 20/10 mmHg above target, or those at high absolute CVD risk. Preferred combinations include an ACEi (or ARB) + CCB or an ACEi (or ARB) + Thiazide-like diuretic .

Beta-Blockers : No longer recommended as first-line monotherapy for uncomplicated primary hypertension because clinical trials show inferior protection against stroke compared to other classes. Beta-blockers are reserved for compelling cardiac indications (angina, HFrEF, post-myocardial infarction, rate control in atrial fibrillation).

Primary references (checked 7 October 2026): Australian CVD risk guideline .